News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Novartis Corporation Says Buys Intercell AG Encephalitis Drug
June 13, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, June 13 (Reuters) - Swiss drugmaker Novartis has bought the rights to market IC51, a late-stage drug for the prevention of Japanese Encephalitis virus infections from Austrian biotech firm Intercell .
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
IPO
2026 IPO stock tracker: How newly public biotechs are performing
July 29, 2026
·
1 min read
·
Gabrielle Masson
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
July 27, 2026
·
3 min read
·
Gabrielle Masson
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
July 27, 2026
·
2 min read
·
Tristan Manalac
Insights
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
July 27, 2026
·
4 min read
·
Jennifer C. Smith-Parker
